RAP - The Next Phase

Hi All, as a RAPper from the beginning, I thought it would be nice to provide a summary of where we are and what we have to expect over the remainder of Q2 for which we now officially enter the 2nd half of the quarter!

From a news-flow perspective, the next 6 weeks could see the following Anns:
- Partner for US trial (imminent)
- Interim Adult trial results
- Update on WHO partnership (possible)
- MOU with telehealth provider (possible)
- Global Expansion Update (possible - see below for more detail)
- FDA Submission (end of Q2)

I would also like to reinforce some excellent points from the latest investor presentation (3 May - note the relevant page numbers of the slides below) which include:
- Targeting parallel approval in Europe (CE MARK) - page 11
- "Active Partnership Discussions in ALL regions" - page 11
- "Clinical collaborations to be announced shortly" - page 13
- "Potential European, Australian and Asian market entry in parallel to US" - page 16

With all of this taken in to consideration, coupled with the passing of 4-weeks since the CR to allow for staggers to exit, it is no coincidence that we saw a rush of volume / price late last week which IMO will continue and be consistently strong until the end of Q2.

Also note that we are presenting in the "ASX Spotlight Series - Asia" in Singapore (24-May) and Hong Kong (26-May). It has been a nice pattern of late that huge milestones are ticked off prior to a fresh round of investor briefings and again, the timing of these presentations to international investors is no coincidence IMO.

I am expecting one of the above milestones to be announced this week which should see RAP hit all time highs (>32c) and then there will be no stopping the train as the remainder of the Q2 milestones are ticked off.

Longer term, $1-$2 by FDA approval is well & truly in sight which will see RAP become a >$1B Mkt Cap company before the end of the year!

A final little note is that we have been consistently trading above 150m Mkt Cap for a while now which will put us in line for ASX300 admission upon the next index rebalance. This will see mandatory buying from index related funds... adding to the RAP demand!!